MGC Pharmaceuticals Ltd is currently undertaking a phase 3 clinical trial of CimetrA in Israel as an investigational medicinal product for the treatment of COVID-19 following successful phase 2 trials in 2020. COVID-19 pandemic − clinical challenges CimetrA is a nanoparticle micellar formulation based on the pharmace
Full Story >>
Vote
+129